Clinical trials: completed, in Cyprus
Amyloidosis, Hereditary, Transthyretin Amyloidosis
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in participants with hereditary transthyretin amyloidosis (hATTR amyloidosis).
- Trial name
- NCT03759379
- Testing
- Patisiran, Vutrisiran
- Where
- 64 sites in United States, Argentina and 20 more
- Volunteers
- 164 people
- Sponsor
- Alnylam Pharmaceuticals
Metastatic Non Small Cell Lung Cancer
Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy
Single arm one stage Phase II study: post 4-6 cycles platinum doublet chemotherapy for patients with metastatic Non Small Cell Lung Cancer (NSCLC) offering Pembrolizumab as maintenance therapy to non-progressors with primary…
- Trial name
- SWIPE (NCT02705820)
- Testing
- Pembrolizumab
- Where
- Cyprus
- Volunteers
- 48 people
- Sponsor
- Bank of Cyprus Oncology Centre
First Line Non-Small Cell Lung Cancer
Avelumab in First-line NSCLC (JAVELIN Lung 100)
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in…
- Trial name
- NCT02576574
- Testing
- Avelumab, Pemetrexed, Paclitaxel
- Where
- 349 sites in United States, Australia and 40 more
- Volunteers
- 1,214 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
The main objective of this study was to evaluate the efficacy of eplontersen as compared with the historical control of the placebo cohort in the NEURO-TTR trial (NCT01737398/2012-001831-30), in subjects with hereditary…
- Trial name
- NCT04136184
- Testing
- Inotersen, Eplontersen
- Where
- 45 sites in United States, Argentina and 14 more
- Volunteers
- 168 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Transthyretin Gene Mutations, Transthyretin Amyloidosis
Transthyretin Amyloidosis Outcome Survey (THAOS)
THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM.
- Trial name
- THAOS (NCT00628745)
- Testing
- None. Observational Study.
- Where
- 113 sites in United States, Argentina and 23 more
- Volunteers
- 6,718 people
- Sponsor
- Pfizer
Soccer, Core Stability
Core Stabilization Programme on Kicking Velocity and Performance in Male Adolescent Football Players
Core stability is an important component maximising efficient athletic function. Function is most often produced by the kinetic chain, the coordinate sequenced activation of body segments that places the distal segment in the…
- Conditions
- Soccer, Core Stability, Sports Performance
- Trial name
- NCT05711069
- Testing
- Core Stability Exercise Program, Routine Football Training Program
- Where
- Cyprus
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
TTR-mediated Amyloidosis, Amyloidosis, Hereditary
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis.
- Conditions
- TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies
- Trial name
- NCT01960348
- Testing
- patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl)
- Where
- 52 sites in United States, Argentina and 19 more
- Volunteers
- 225 people
- Sponsor
- Alnylam Pharmaceuticals
Amyloidosis
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
- Trial name
- NCT02510261
- Testing
- Patisiran
- Where
- 56 sites in United States, Argentina and 19 more
- Volunteers
- 211 people
- Sponsor
- Alnylam Pharmaceuticals
Nicotine Dependence, Smoking Cessation
Accelerated iTBS in Smoking Cessation
Cigarette smoking is one of the foremost causes of preventable disease and premature death. In 2014, 68% of adult smokers wanted to quit smoking and in 2017, 55.1% of adult smokers had made a quit attempt.
- Trial name
- NCT05271175
- Testing
- Active intermittent theta burst stimulation
- Where
- Cyprus
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Cyprus rTMS Center
Stroke, Hemiparesis
The Comparison of Virtual and Real Boxing Training in Hemiparetic Stroke Patients
The aim of this study is to compare the effects of virtual and real boxing training in addition to neurodevelopmental training on cognitive status, upper extremity functions, balance and activities of daily living in hemiparetic…
- Trial name
- NCT03651479
- Testing
- real boxing training, virtual boxing training
- Where
- Cyprus
- Volunteers
- 40 people
- Sponsor
- Eastern Mediterranean University
Advanced Pancreatic Cancer
A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL), clinical signs and symptoms of disease, selected…
- Trial name
- NCT01303172
- Testing
- IMM-101, Gemcitabine
- Where
- 21 sites in Cyprus, Ireland and 3 more
- Volunteers
- 110 people
- Sponsor
- Immodulon Therapeutics Ltd
Polycystic Ovary Syndrome, c Type Natriuretic Peptide
Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women
Recent studies have shown that C natriuretic peptide is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.
- Conditions
- Polycystic Ovary Syndrome, c Type Natriuretic Peptide, Menstrual Irregularity, Hyperandrogenism
- Trial name
- CNP (NCT04006171)
- Testing
- C type natriuretic peptide
- Where
- Cyprus
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Near East University, Turkey
Thrombocythemia, Essential
Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments
This is an observational safety study being conducted in Europe comparing patients taking Xagrid to patients taking other cytoreductive treatments.
- Trial name
- NCT00567502
- Where
- 164 sites in Cyprus, Denmark and 12 more
- Volunteers
- 3,647 people
- Sponsor
- Shire
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures
- Trial name
- NCT00988429
- Testing
- 800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate
- Where
- 162 sites in United States, Argentina and 9 more
- Volunteers
- 653 people
- Sponsor
- Bial - Portela C S.A.
Chronic Iron Overload
Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate efficacy and safety of a 12-months treatment with deferiprone (DFP) at dose of 75-100 mg/kg/day versus deferasirox (DFX) at dose of 20-40…
- Trial name
- NCT01825512
- Testing
- Deferiprone, Deferasirox
- Where
- 22 sites in Albania, Cyprus and 5 more
- Volunteers
- 435 people
- Sponsor
- Consorzio per Valutazioni Biologiche e Farmacologiche
Chronic Heart Failure (CHF)
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if…
- Trial name
- PREFER (NCT02807857)
- Testing
- Standard care
- Where
- 191 sites in Belgium, Croatia and 16 more
- Volunteers
- 1,415 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
This open-label, multicenter, non-randomized study provided continued access to vemurafenib for eligible participants with BRAF V600 mutation-positive malignancy, who were previously enrolled and treated in an antecedent…
- Trial name
- NCT01739764
- Testing
- Vemurafenib
- Where
- 83 sites in United States, Belarus and 23 more
- Volunteers
- 215 people
- Sponsor
- Hoffmann-La Roche
Upper Extremity Injury, Sport Injury
Throwers Ten Exercises On Upper Extremity Function and Explosive Power in Wheelchair Basketball and Basketball Players
Basketball is a challenging sport that requires participants to demonstrate physical fitness and special athletic skills at high levels.
- Conditions
- Upper Extremity Injury, Sport Injury, Shoulder Pain, Muscle Weakness
- Trial name
- NCT04019990
- Testing
- The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players
- Where
- Cyprus
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Serum CNP Levels, Healthy Reproductive Age Women
Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods
Recent studies have shown that C natriuretic peptide (CNP) is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors.It has…
- Conditions
- Serum CNP Levels, Healthy Reproductive Age Women, Healthy Perimenopausal Women, Healthy Postmenopausal Women
- Trial name
- CO (NCT04000815)
- Testing
- C Type Natriüretic Peptide
- Where
- Cyprus
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Near East University, Turkey
Chronic Iron Overload
Pharmacokinetic Study of Deferiprone in Paediatric Patients
Deferiprone (DFP) is the most extensively studied oral iron chelator to date. It has been authorised in Europe in 1999 for the treatment of iron overload in patients with beta-thalassaemia major when DFO is contraindicated or…
- Trial name
- DEEP-1 (NCT01740713)
- Testing
- Deferiprone, dose level 1, Deferiprone, dose level 2, Deferiprone, dose level 3
- Where
- 7 sites in Cyprus, Egypt and 1 more
- Volunteers
- 23 people
- Sponsor
- Consorzio per Valutazioni Biologiche e Farmacologiche